Surrozen, Inc.
NASDAQ:SRZN · NASDAQ Capital Market
+$0.02 today
Vol 0.10M · Avg 0.10M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
128.9%
avg 9.4%
ROIC
-46.7%
avg -62.0%
ROA
-245.1%
avg -94.0%
Analysis
ROE is currently the strongest return metric at 128.9% versus its period average of 9.4%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Craig C. Parker | Chief Executive Officer, President & Director | $976,500.00 | — | 64 | $16,553.00 | 0.22% |
Charles Williams | Chief Operating Officer & Corporate Secretary | $689,786.00 | — | 46 | $16,571.00 | 0.22% |
Yang Li | Executive Vice President of Research | $642,100.00 | — | 57 | $17,216.00 | 0.23% |
Roeland Nusse | Co-Founder & Member of Scientific Advisory Board | — | — | 76 | — | — |
Esther Jhun | Controller | — | — | — | — | — |
Calvin Kuo | Co-Founder & Member of Scientific Advisory Board | — | — | — | — | — |
K. Christopher Garcia | Co-Founder & Member of Scientific Advisory Board | — | — | — | $5,550.00 | 0.07% |
Daniel L. Chao | Vice President and Head of Clinical Development | — | — | — | — | — |
Andrew Maleki | Chief Financial Officer | — | — | 36 | $50,000.00 | 0.67% |
Michael Lauw | Senior Vice President of Development Operations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
56
$16.85M
Sells
5
$324,780.52
Net Sentiment
+$16.52M
Net buying
Most Active
TCG Crossover GP II, LLC
20 transactions
1–10 of 61
Analysis
Insiders reported 56 buys worth $16.85M and 5 sells worth $324,780.52 over the last 12 months. That adds up to net buying of $16.52M. TCG Crossover GP II, LLC was the most active insider with 20 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Immix Biopharma, Inc.
NASDAQ:IMMX
$459.70M
Greenwich LifeSciences, Inc.
NASDAQ:GLSI
$353.16M
Opus Genetics, Inc.
NASDAQ:IRD
$328.84M
Agenus Inc.
NASDAQ:AGEN
$137.42M
Seer, Inc.
NASDAQ:SEER
$94.57M
Cognition Therapeutics, Inc.
NASDAQ:CGTX
$89.03M
Instil Bio, Inc.
NASDAQ:TIL
$53.71M
Tevogen Bio Holdings Inc.
TVGN
$43.84M
Atossa Therapeutics, Inc.
ATOS
$21.18M
VistaGen Therapeutics, Inc.
VTGN
$18.88M
Who manages SRZN?
Surrozen, Inc. (SRZN) lists 10 active executives. The top listed executive is Roeland Nusse, Co-Founder & Member of Scientific Advisory Board.
Are SRZN insiders buying or selling?
Recent insider activity shows net buying of $124.03M.
Explore More
Continue the stock analysis
Jump to another research area for this company.